China begins to snap at America’s heels in a tightening tech race

    The recent news about China developing the world’s fastest supercomputer will trigger the predictable debate about whether Beijing has finally overtaken the US in advanced computing. The answer, at least for now, is no. The new LineShine system that topped the latest TOP500 ranking is not the world’s most powerful machine for artificial intelligence (AI)…

    Read More
    Key Speakers at the China Development Forum

      Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration

      David Ricks, chief executive officer of Eli Lilly & Co., speaks during the China Development Forum in Beijing in March this year. Photographer: Qilai Shen/Bloomberg © 2026 Bloomberg Finance LP In the latest China pharmaceutical industry collaboration pact with a global drug leader, Abbisko said today it will work with U.S.-based Eli Lilly and Company…

      Read More
      ‘Tour de force’ by Chinese chemists could overturn high cost of drug treatments

      ‘Tour de force’ by Chinese chemists could overturn high cost of drug treatments

      Scientists in China have solved a 140-year-old chemistry problem in a breakthrough that could overturn traditional production methods and slash the cost of cancer treatments and other expensive medicinal compounds. The research was co-led by Zhang Xiaheng, from the Chinese Academy of Sciences’ Hangzhou Institute for Advanced Study, and Xue Xiaosong, a professor with the…

      Read More
      FDA authorizes updated COVID vaccines with restrictions on who can get them

      FDA authorizes updated COVID vaccines with restrictions on who can get them

      The Food and Drug Administration Wednesday authorized updated COVID-19 vaccines, but limited their use for most age groups and rescinded the emergency use authorization that made shots available for healthy young children. Vaccines from Pfizer, Moderna and Novavax are approved for all seniors, but only for younger adults and children with health conditions.  The decision means…

      Read More

      Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program

      Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer, Inc. (NYSE:PFE) have announced a direct-to-patient program for Eliquis (apixaban), their top-selling blood thinner, in a move aimed at improving access for uninsured and underinsured patients. Starting September 8, 2025, eligible individuals will be able to…

      Read More